|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Inventory impairment charges | |||||
| Amortization of inventory step-up | |||||
| Allowance for credit losses and inventory reserves | |||||
| Share-based compensation | |||||
| Amortization of discount and cost of issuance of debt | |||||
| Gain from change in fair value remeasurement of SAFEs | |||||
| Asset impairment in relation to restructuring | |||||
| Gain from change in fair value of warrants | |||||
| Loss from change in fair value of earn-out liabilities | |||||
| (Gain) loss from change in fair value of contingent considerations and acquisition-related holdbacks | |||||
| (Gain) loss from change in fair value of currency forward contract | |||||
| Gain from extinguishment of debt | |||||
| Deferred City Semi compensation | |||||
| Deferred tax liabilities | |||||
| Amortization of right-of-use assets | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventory | |||||
| Accounts payable | |||||
| Accrued expenses and other current liabilities | |||||
| Accrued payroll liabilities | |||||
| Deferred revenue | |||||
| Prepaid, other current and noncurrent assets | |||||
| Operating lease liabilities | |||||
| Other long-term liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Purchases of intangible assets | |||||
| Payments for acquired software license | |||||
| Business combinations, net of cash acquired | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from issuance of SAFEs | |||||
| Proceeds from reverse recapitalization | |||||
| Issuance costs related to reverse recapitalization | |||||
| Redemption of Class H units | |||||
| Proceeds from issuance of common stock/At-the-market offering | |||||
| Offering costs for the issuance of common stock/At-the-market offering | |||||
| Proceeds from Wuxi Capital Raise | |||||
| Issuance costs related to Wuxi Capital Raise | |||||
| Wuxi EIP capital paid in | |||||
| 2029 convertible note capped call transactions | |||||
| Proceeds from issuance of debt obligations | |||||
| Issuance and debt discount costs related to debt obligations | |||||
| Repurchase of common stock | |||||
| Repurchase of debt obligations | |||||
| Payments on debt obligations | |||||
| Payments on financed software | |||||
| Deferred payments on business combination | |||||
| Taxes paid related to net share settlement of vested equity awards | |||||
| Proceeds from exercise of stock options | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rate changes on cash, and cash equivalents | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for taxes | |||||
| Cash paid for interest | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Conversion of historical members' equity | |||||
| Class G warrants cashless exchange | |||||
| Conversion of SAFEs | |||||
| Conversion of Embry Notes | |||||
| Recognition of earn-out considerations | |||||
| Recognition of warrant liabilities | |||||
| Accrual for purchases of intangible assets | |||||
| Purchases of property and equipment, accrued but not paid | |||||
| Fair value of common stock issued for investment in Expedera | |||||
| Fair value of common stock issued for business combination | |||||
| Fair value of common stock issued to satisfy contingent considerations and acquisition-related holdbacks | |||||
| Fair value of common stock issuable for business combination | |||||
| Contingent consideration for business combination | |||||
| Accrual for purchase consideration for business combination | |||||
Loading...